Evaluación económica e impacto presupuestario del stent recubierto Endeavor？ en Espa？a

objectives: endeavor？ is a drug-eluting stent (des) with superior results to the bare metal stent (bms) and similar efficacy to other des in terms of revascularization. the aim of this study was to assess the costs and benefits of endeavor？, other des, bms and coronary artery bypass grafts (cabg) in spain. methods: a markov model with a 5-year time was used to reflect the management of patients with de novo coronary artery lesions in spain. model probabilities were derived from systematic reviews and randomized controlled trials of endeavor？. health resources and costs were obtained from local data and were validated by experts. effectiveness was measured as the number of revascularizations avoided, the major adverse coronary events (mace) avoided and the quality adjusted life-years (qalys) gained. results: endeavor？ had higher total costs than the bms. the cost per revascularization avoided with endeavor？ was 6,851 € (at 1 year) and 10,831 € (at 5 years). in terms of cost per mace avoided with endeavor？, the results were 7,003 € and 11,322 €, respectively, and in terms of costs of qaly gained were 132,877 €, 34,229 € and 10,505 € at 1, 2, and 5 years, respectively. the budget impact of the progressive introduction of endeavor？ would be practically null, representing 0.4% of the total cost of percutaneous coronary interventions at 5 years. conclusions: the use of the endeavor？ stent compared with bms and cabg represents efficient resource use in patients with coronary artery disease, with cost-effectiveness results below the threshold of efficiency defined in spain.